Approach to the Pediatric Patient With Glucocorticoid-Induced Osteoporosis - Takeaways - MDSpire

Approach to the Pediatric Patient With Glucocorticoid-Induced Osteoporosis

  • By

  • Leanne M Ward

  • Sarah A Bakhamis

  • Khaldoun Koujok

  • August 10, 2024

  • 0 min

Share

  • 1

    Glucocorticoid therapy is a major cause of osteoporosis in pediatric patients, impacting skeletal health and increasing fracture risk.

  • 2

    Early identification of vertebral fractures is crucial in managing pediatric glucocorticoid-induced osteoporosis to prevent further complications.

  • 3

    Intravenous bisphosphonates are the first-line treatment for pediatric glucocorticoid-induced osteoporosis, though they may not fully prevent progression.

  • 4

    The STOPP Consortium study highlights that vertebral fractures often occur early in glucocorticoid treatment and can be asymptomatic.

  • 5

    Growth-mediated vertebral body reshaping can aid recovery in pediatric patients, potentially reducing the need for osteoporosis therapy.

Original Source(s)

Approach to the Pediatric Patient With Glucocorticoid-Induced Osteoporosis

  • by Leanne M Ward, Sarah A Bakhamis, Khaldoun Koujok

  • August 10, 2024

Related Content

Severe IL-6–dominant immune-mediated inflammatory response complicated by probable arginine vasopressin deficiency following ivonescimab-based therapy in advanced EGFR-mutant lung squamous cell carcinoma: a case report

MiR-1a-3p/Fcgr4-dependent osteoclast activation regulates pathological bone loss

Chronic psychosocial stress: a role in breast cancer etiology?